Enlivex Therapeutics (NASDAQ:ENLV) Issues Earnings Results

Enlivex Therapeutics (NASDAQ:ENLV) released its quarterly earnings data on Monday. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.07), Zacks reports.

Enlivex Therapeutics Trading Down 1.1 %

NASDAQ ENLV traded down $0.01 during trading hours on Wednesday, reaching $0.94. 19,643 shares of the company’s stock were exchanged, compared to its average volume of 154,229. The firm has a fifty day moving average of $1.09 and a 200-day moving average of $1.23. Enlivex Therapeutics has a one year low of $0.81 and a one year high of $4.59. The stock has a market cap of $20.12 million, a PE ratio of -0.96 and a beta of 1.11.

Analyst Ratings Changes

A number of analysts have weighed in on the company. D. Boral Capital reiterated a “buy” rating and issued a $13.00 price target on shares of Enlivex Therapeutics in a research report on Monday, March 3rd. HC Wainwright upped their target price on shares of Enlivex Therapeutics from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Monday, March 24th.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.